Application of sedoheptulose to preparation of new anti-hepatitis B medicament

Abstract

The invention discloses application of sedoheptulose to the preparation of a new anti-hepatitis B medicament. The structural formula of the sedoheptulose is disclosed in the specification. Proved by a 2.2.1.5 cell line in vitro experiment and an in vivo experiment of a hepatitis B virus infected duck, the sedoheptulose can effectively suppress the activity of the hepatitis B viruses.

Description

technical field The present invention relates to the use of ketone anhydrous glycosides, in particular to its medical use. Background technique Hepatitis B is one of the important infectious diseases that endanger human health. About 10% of people in China carry HBsAg. Although the medicines for the treatment of hepatitis B are developing rapidly at present, most of them have rebound phenomenon after drug withdrawal. Interferon, which was introduced into my country in the 1970s, has a recognized curative effect of only 30%. After various improvements in dosage forms and treatment methods, it is only about 40%. Nucleoside drugs developed later, such as arabinocytosin Glycosides, acyclovir, lamivudine, adefovir, entecavir, etc., although the curative effect has been greatly improved, but there are varying degrees of drug withdrawal rebound phenomenon, so that there is a "stopping treatment" phenomenon in the treatment of hepatitis B. The phenomenon of relapsing after taking me...

AI Technical Summary

Problems solved by technology

The patent No. is 99112550.9, and the application date is July 26, 1996. The Chinese patent discloses the application of the above-mentioned promethazone anhydride in the preparation of anti-hepatitis B drugs. The application in has not yet been identified

Images